Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Clearside Biomedical Inc CLSD

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:CLSD)

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 10 days ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

GlobeNewswire November 7, 2024

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

GlobeNewswire November 6, 2024

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

GlobeNewswire November 4, 2024

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

GlobeNewswire October 31, 2024

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

GlobeNewswire October 22, 2024

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

GlobeNewswire October 9, 2024

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

GlobeNewswire August 27, 2024

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2024

Opinion & Analysis (NDAQ:CLSD)

No current opinion is available.

Bullboard Posts (NDAQ:CLSD)

CLSD .... ER surprise !!!!!

Cha -Ching !
Iseneschal - March 11, 2022

still holding this stock

it's climbing up steadily,so glta shareholders.
coolfooldumbguy - January 28, 2020

it's time to go up again

so glta shareholders.
coolfooldumbguy - January 21, 2020

still holding this stock

almost a year,that's a long term hold for me,but it is moving up steadily,so glta.
coolfooldumbguy - January 17, 2020

it's a buy today for me

got in this morning at $1.65 per share,so glta.
coolfooldumbguy - February 20, 2019